About: Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways
Creator	Tang, Chen Wang, Hai-Xu
Source	PMC
abstract	Laryngeal cancers are mostly squamous cell carcinomas. Although targeting radio-resistant cancer cells is important for improving the treatmental efficiency, the signaling pathway- and therapeutic strategy-related to laryngeal carcinoma still require further study. Galangin is an active pharmacological ingredient, isolated from propolis and Alpinia officinarum Hance, and has been reported to have anticancer and anti-oxidative properties through regulation of cell cycle, resulting in angiogenesis, apoptosis, invasion and migration without triggering any toxicity in normal cells. PI3K/AKT and p38 are important signaling pathways to modulate cancer cell apoptosis and proliferation through caspase-3, NF-κB and mTOR signal pathways. Autophagy is also enhanced by activating LC3s and Beclin 1. In the present study, galangin was found to suppress laryngeal cancer cell proliferation. Also, flow cytometry, immunohistochemical and western blot analysis indicated that cell apoptosis was induced for galangin administration, promoting caspase-3 expression through regulating PI3K/AKT/NF-κB. Furthermore, galangin inhibited laryngeal cancer cell proliferation, related to p38 inactivation by galangin treatment. Additionally, mTOR activation regulated by PI3K/AKT was reduced by galangin, suppressing cancer cell transcription and proliferation. Our data also indicated that the tumor volume and weight in nude mice were reduced for galangin use in vivo accompanied by Ki-67 decrease and TUNEL increase in tumor tissues. Together, our data indicated that galangin has a potential role in suppressing human laryngeal cancer via inhibiting tumor cell proliferation, activating apoptosis and autophagy, which were regulated by p38 and AKT/NF-κB/mTOR pathways, providing a therapeutic strategy for human laryngeal cancer treatment.
has issue date	2017-06-29(xsd:dateTime)
bibo:doi	10.3892/or.2017.5767
bibo:pmid	28677816
has license	cc-by-nc-nd
sha1sum (hex)	073f69cb524332da71737facd889ffefd4aafa46
schema:url	https://doi.org/10.3892/or.2017.5767
resource representing a document's title	Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways
has PubMed Central identifier	PMC5562077
has PubMed identifier	28677816
schema:publication	Oncol Rep
resource representing a document's body	covid:073f69cb524332da71737facd889ffefd4aafa46#body_text
is schema:about of	named entity 'enhanced' named entity 'weight' named entity 'NF-κB' named entity 'modulate' named entity 'cells' named entity 'pathways' named entity 'caspase' named entity 'AKT' named entity 'vivo' named entity 'cancer' named entity 'proliferation' named entity 'cell cycle' named entity 'activating' named entity 'autophagy' named entity 'galangin' named entity 'WESTERN BLOT ANALYSIS' named entity 'RESISTANT CANCER' named entity 'INACTIVATION' named entity 'tumor cell' named entity 'activation' named entity 'mTOR' named entity 'laryngeal cancer' named entity 'mTOR' named entity 'study' named entity 'galangin' named entity 'cell proliferation' named entity 'therapeutic' named entity 'regulated' named entity 'administration' named entity 'regulating' named entity 'Galangin' named entity 'Laryngeal' named entity 'PI3K/AKT' named entity 'galangin' named entity 'cancer cell' named entity 'caspase-3' named entity 'anti-oxidative' named entity 'p38' named entity 'apoptosis' named entity 'NF-κB' named entity 'mTOR' named entity 'flow cytometry' named entity 'signaling pathways' named entity 'Although' named entity 'TUNEL' named entity 'La Jolla' named entity 'galangin' named entity 'Bcl-2' named entity 'downregulated' named entity 'cell death' named entity 'Ki-67' named entity 'galangin' named entity 'signaling pathways' named entity 'galangin' named entity 'bioactivities' named entity 'galangin' named entity 'epithelial cells' named entity 'homeostasis' named entity 'cancer cells' named entity 'galangin' named entity 'Ki-67' named entity 'inflammatory response' named entity 'galangin' named entity 'KeyGen' named entity 'melanoma' named entity 'autophagy' named entity 'SDS-PAGE' named entity 'upper chamber' named entity 'autophagy' named entity 'larynx' named entity 'laryngeal carcinoma' named entity 'IκB' named entity 'galangin' named entity 'Immobilon' named entity 'galangin' named entity 'galangin' named entity 'Corning Inc.' named entity 'galangin' named entity 'anti-tumor agent' named entity 'laryngeal carcinoma'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software